Combined intake of caffeine and low‐dose glucose to reduce exercise‐related hypoglycaemia in individuals with type 1 diabetes on ultra‐long‐acting insulin degludec: A randomized, controlled, double‐blind, cross‐over trial
Open Access
- 1 April 2024
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (7) , 2645-2651
Abstract
Aim: To evaluate whether caffeine combined with a moderate amount of glucose reduces the risk for exercise‐related hypoglycaemia compared with glucose alone or control in adult people with type 1 diabetes using ultra‐long‐acting insulin degludec. Materials and Methods: Sixteen participants conducted three aerobic exercise sessions (maximum 75 min) in a randomized, double‐blind, cross‐over design. Thirty minutes before exercise, participants ingested a drink containing either 250 mg of caffeine + 10 g of glucose + aspartame (CAF), 10 g of glucose + aspartame (GLU), or aspartame alone (ASP). The primary outcome was time to hypoglycaemia. Results: There was a significant effect of the condition on time to hypoglycaemia (χ 2 = 7.674, p = .0216). Pairwise comparisons revealed an 85.7% risk reduction of hypoglycaemia for CAF compared with ASP ( p = .044). No difference was observed between GLU and ASP ( p = .104) or between CAF and GLU ( p = .77). While CAF increased glucose levels during exercise compared with GLU and ASP (8.3 ± 1.9 mmol/L vs. 7.7 ± 2.2 mmol/L vs. 5.8 ± 1.4 mmol/L; p < .001), peak plasma glucose levels during exercise did not differ between CAF and GLU (9.3 ± 1.4 mmol/L and 9.1 ± 1.6 mmol/L, p = .80), but were higher than in ASP (6.6 ± 1.1 mmol/L; p < .001). The difference in glucose levels between CAF and GLU was largest during the last 15 min of exercise ( p = .002). Compared with GLU, CAF lowered perceived exertion ( p = .023). Conclusions: Pre‐exercise caffeine ingestion combined with a low dose of glucose reduced exercise‐related hypoglycaemia compared with control while avoiding hyperglycaemia.Keywords
Funding Information
- Novo Nordisk Pharma
- Dexcom
This publication has 27 references indexed in Scilit:
- The effect of acute caffeine intake on insulin sensitivity and glycemic control in people with diabetesDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2017
- Exercise management in type 1 diabetes: a consensus statementThe Lancet Diabetes & Endocrinology, 2017
- A review of caffeine’s effects on cognitive, physical and occupational performanceNeuroscience & Biobehavioral Reviews, 2016
- Metabolic and hormonal response to intermittent high-intensity and continuous moderate intensity exercise in individuals with type 1 diabetes: a randomised crossover studyDiabetologia, 2016
- A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical RelevanceClinical Pharmacokinetics, 2014
- Association of physical activity with all-cause mortality and incident and prevalent cardiovascular disease among patients with type 1 diabetes: the EURODIAB Prospective Complications StudyDiabetologia, 2012
- Pyruvate carboxylase is expressed in human skeletal muscleBiochemical and Biophysical Research Communications, 2010
- Carbohydrate requirement and insulin concentration during moderate exercise in type 1 diabetic patientsMetabolism, 2004
- Effect of caffeine on recognition of and physiological responses to hypoglycaemia in insulin-dependent diabetesThe Lancet, 1996
- Subclasses of adenosine receptors in the central nervous system: Interaction with caffeine and related methylxanthinesCellular and Molecular Neurobiology, 1983